Difference between revisions of "SPECT Biomarker Ctte"
Jump to navigation
Jump to search
Line 13: | Line 13: | ||
==Profile Development== | ==Profile Development== | ||
− | :[[Media:001 QIBA_SPECT_Profile v0 1 JCD 2016 01 21.docx| QIBA DRAFT Profile: Quantifying Dopamine Transporters with 123-Iodine Labeled Ioflupane in Neurodegenerative Disease(Short Title: QIBA DRAFT Profile: SPECT dopamine transporters)]] ''January 22, 2016'' | + | :[[Media:001 QIBA_SPECT_Profile v0 1 JCD 2016 01 21.docx| QIBA DRAFT Profile: Quantifying Dopamine Transporters with 123-Iodine Labeled Ioflupane in Neurodegenerative Disease (Short Title: QIBA DRAFT Profile: SPECT dopamine transporters)]] ''January 22, 2016'' |
==Statistical Reference Documents== | ==Statistical Reference Documents== |
Revision as of 22:22, 22 January 2016
Project Snapshot
The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.
Under consideration:
- quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
- quantifying organs, like the liver, for dosimetry as potential use cases
Meetings/Call Summaries
Working Documents
Profile Development
Statistical Reference Documents
Workflow Documents
Reference Materials
- Quantification and Image Analysis Task Force presentation slides - Dr. Miyaoka January 12, 2016
- Quantification and Image Analysis Task Force presentation slides - Dr. Seibyl January 12, 2016
- I-123 DAT SCAN - Acquisition and Reconstruction Task Force presentation slides - Dr. Dewaraja January 5, 2016
- QIBA Claim Statement Types - Dr. Obuchowski November 20, 2015
- 03.20.2015 Link to papers of the group in Umeå that are collaborating with Dr. Ljungberg:
- The PI for this is Anne Larsson, PhD: http://www.ncbi.nlm.nih.gov/pubmed/?term=dat+scan+Larsson+A